T Straatmijer et al. Clin Gastroenterol Hepatol 2022; Full text Pre-Proof PDF: Superior effectiveness of tofacitinib compared to vedolizumab in anti-TNF experienced ulcerative colitis patients: a nationwide Dutch Registry study. DOI:https://doi.org/10.1016/j.cgh.2022.04.038

Methods: Ulcerative colitis patients who failed anti-TNF treatment and initiated vedolizumab (n=83) or tofacitinib (n=65) treatment, were identified in the ICC Registry in the Netherlands.

Key findings:

• Tofacitinib treated patients were more likely to achieve corticosteroid-free clinical remission and biochemical remission at week 12, 24 and 52 compared to vedolizumab treated patients (OR: 6.33, OR: 3.02, and OR 1.86 and OR: 3.27, OR: 1.87, and OR:1.81, respectively).
• There was no difference in infection rate or severe adverse events.

My take: The response rates with tofacitinib were significantly better than vedolizumab at all time points; however, by 52 weeks, the differences were less pronounced. Nevertheless, the safety profile of vedolizumab is much more favorable than tofacitinib and this is a very important consideration.

Related blog posts -Tofacitinib:

• IBD Shorts: Tofacitinib Safety, Vedolizumab for EIM
• AGA Guidelines: Moderate to Severe Ulcerative Colitis
• FDA Slaps Restrictions on JAK Inhibitors Over Serious Safety Risks (2021)
• A New FDA Warning for Tofacitinib (2021)
• FDA Warning on Tofacitinib (2019)
• “Tofacitinib: A Jak of All Trades”
• Comparative Efficacy: Vedolizumab vs Anti-TNF Agents
• “Positioning Biologic Therapies in the Management of Pediatric Inflammatory Bowel Disease” & 14% of U.S. Infected with COVID-19 | gutsandgrowth